Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - zidovudine, quantity: 250 mg - capsule, hard - excipient ingredients: gelatin; maize starch; microcrystalline cellulose; sodium starch glycollate; magnesium stearate; indigo carmine; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid; potassium hydroxide - retrovir is indicated for: . treatment of adult patients with severe symptomatic human immunodeficiency virus infection (aids or advanced aids related complex); . treatment of other hiv-positive adult patients with less than 500 cd4 cells/mm3. notes: (1) the limited available data currently support the extended use of retrovir (indication 2 above). (2) the optimal dosage for these indications has not been established. . combination therapy in advanced hiv infection. the addition of hivid (zalcitabine) may be considered for the management of adult patients with advanced hiv infection and cd4 + cell counts less than or equal to 200/mm3, who have received retrovir monotherapy for less than 12 months. retrovir monotherapy is still indicated as initial therapy for adult patients with hiv infection who fulfil the approved indications. new indications approved 7th february 1997: retrovir (zidovudine) is indicated for the treatment of hiv infection, alone and in combination with other antiretroviral therapies. the

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - zidovudine, quantity: 100 mg - capsule - excipient ingredients: sodium starch glycollate; microcrystalline cellulose; maize starch; magnesium stearate; titanium dioxide; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid; potassium hydroxide - retrovir is indicated for: . treatment of adult patients with severe symptomatic human immunodeficiency virus infection (aids or advanced aids related complex); . treatment of other hiv-positive adult patients with less than 500 cd4 cells/mm3. notes: (1) the limited available data currently support the extended use of retrovir (indication 2 above). (2) the optimal dosage for these indications has not been established. . combination therapy in advanced hiv infection. the addition of hivid (zalcitabine) may be considered for the management of adult patients with advanced hiv infection and cd4 + cell counts less than or equal to 200/mm3, who have received retrovir monotherapy for less than 12 months. retrovir monotherapy is still indicated as initial therapy for adult patients with hiv infection who fulfil the approved indications. new indications approved 7th february 1997: retrovir (zidovudine) is indicated for the treatment of hiv infection, alone and in combination with other antiretroviral therapies. the

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - zidovudine - capsules - zidovudine 100 mg - zidovudine - zidovudine - retrovir oral formulations are indicated in anti-retroviral combination therapy for human immunodeficiency virus (hiv) infected adults and children.retrovir chemoprophylaxis is indicated for use in hiv-positive pregnant women (over 14 weeks of gestation) for prevention of maternal-foetal hiv transmission and for primary prophylaxis of hiv infection in newborn infants.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - zidovudine - capsules - zidovudine 250 mg - zidovudine - zidovudine - retrovir oral formulations are indicated in anti-retroviral combination therapy for human immunodeficiency virus (hiv) infected adults and children.retrovir chemoprophylaxis is indicated for use in hiv-positive pregnant women (over 14 weeks of gestation) for prevention of maternal-foetal hiv transmission and for primary prophylaxis of hiv infection in newborn infants.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - zidovudine - solution for infusion - zidovudine 200 mg / 20 ml - zidovudine - zidovudine - retrovir iv for infusion is indicated for the short term management of serious manifestations of human immunodeficiency virus (hiv) infection in patients with acquired immuno deficiency syndrome (aids) or aids who are unable to take retrovir oral formulations.retrovir chemoprophylaxis, is indicated for use in hiv-positive pregnant women (over 14 weeks of gestation) for prevention of maternal-foetal hiv transmission and for primary prophylaxis of hiv infection in newborn infants. retrovir i.v. should only be used when oral treatment is not possible (except during labour and delivery).

United States - English - NLM (National Library of Medicine)

viiv healthcare company - zidovudine (unii: 4b9xt59t7s) (zidovudine - unii:4b9xt59t7s) - zidovudine 100 mg - retrovir, a nucleoside reverse transcriptase inhibitor, is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection. retrovir is indicated for the prevention of maternal-fetal hiv-1 transmission [see dosage and administration (2.3)]. the indication is based on a dosing regimen that included 3 components: points to consider prior to initiating retrovir in pregnant women for the prevention of maternal-fetal hiv-1 transmission include: retrovir is contraindicated in patients who have had a potentially life-threatening hypersensitivity reaction (e.g., anaphylaxis, stevens-johnson syndrome) to any of the components of the formulations. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to retrovir during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no difference in the o

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - zidovudine, quantity: 10 mg/ml - oral liquid, solution - excipient ingredients: citric acid; glycerol; maltitol solution; purified water; sodium benzoate; saccharin sodium; flavour - (1) treatment of adult patients with severe symptomatic human immunodeficiency virus infection (aids or advanced aids related complex). (2) treatment of other hiv-positive adult patients with less than 500 cd4 cells/mm3. new indications as at 11 may 1994: retrovir is indicated for: . treatment of adult patients with severe symptomatic human immunodeficiency virus infection (aids or advanced aids related complex); . treatment of other hiv-positive adult patients with less than 500 cd4 cells/mm3. notes: (1) the limited available data currently support the extended use of retrovir (indication 2 above). (2) the optimal dosage for these indications has not been established . combination therapy in advanced hiv infection: the addition of hivid (zalcitabine) may be considered for the management of adult patients with advanced hiv infection and cd4 + cell counts less than or equal to 200/mm3, who have received retrovir monotherapy for less than 12 months. retrovir monotherapy is still indicated as initial therapy f

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - zidovudine - capsules - zidovudine 250 mg - zidovudine - retrovir oral formulations are indicated in anti-retroviral combination therapy for human immunodeficiency virus (hiv) infected adults and children.retrovir chemoprophylaxis is indicated for use in hiv-positive pregnant women (over 14 weeks of gestation) for prevention of maternal-foetal hiv transmission and for primary prophylaxis of hiv infection in newborn infants.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - zidovudine - solution - zidovudine 10 mg/ml - zidovudine - retrovir oral formulations are indicated in anti-retroviral combination therapy for human immunodeficiency virus (hiv) infected adults and children.retrovir chemoprophylaxis is indicated for use in hiv-positive pregnant women (over 14 weeks of gestation) for prevention of maternal-foetal hiv transmission and for primary prophylaxis of hiv infection in newborn infants.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - zidovudine 100mg - capsule - 100 mg - active: zidovudine 100mg excipient: gelatin ink magnesium stearate maize starch microcrystalline cellulose sodium starch glycolate - retrovir oral formulations are indicated in combination with other anti-retroviral agents for the treatment of human immunodeficiency virus (hiv) infection in adults and children.